Your browser of choice has not been tested for use with Barchart.com. If you have issues, please download one of the browsers listed here.
or
Menu

Mersana Therapeutics Inc (MRSN)

[[ item.lastPrice ]] [[ item.priceChange ]] ([[ item.percentChange ]]) [[ item.tradeTime ]] [NASDAQ]
[[ item.bidPrice ]] x [[ item.bidSize ]] [[ item.askPrice ]] x [[ item.askSize ]]
[[ session ]] by (Cboe BZX)
[[ item.lastPrice ]] [[ item.priceChange ]] ([[ item.percentChange ]]) [[ item.tradeTime ]] [NASDAQ]
[[ item.bidPrice ]] x [[ item.bidSize ]] [[ item.askPrice ]] x [[ item.askSize ]]
[[ session ]] [[ item.lastPriceExt ]] [[ item.priceChangeExt ]] ([[ item.percentChangeExt ]]) [[ item.tradeTimeExt ]]
Quote Overview for [[ item.sessionDateDisplayLong ]]
[[ rowChartData.labelLow ]]
[[ rowChartData.lowPriceFormatted ]]
[[ rowChartData.lowPrice ]]
[[ rowChartData.labelHigh ]]
[[ rowChartData.highPriceFormatted ]]
[[ rowChartData.highPrice ]]
since [[ rowChartData.lowDate ]]
since [[ rowChartData.highDate ]]
[[ fieldTitles[key] ]] [[ value ]] [[ value ]]
Realtime quote and/or trades are not sourced from all markets.

Fundamentals

See More
  • Market Capitalization, $K 267,383
  • Shares Outstanding, K 23,150
  • Annual Sales, $ 17,550 K
  • Annual Income, $ -38,710 K
  • 36-Month Beta -1.82
  • Price/Sales 15.02
  • Price/Cash Flow N/A
  • Price/Book 5.70

Analyst Rating / Earnings Estimates

Current Rating
See More
Moderate Buy
Based on 6 analysts offering recommendations.
Earnings Estimates - Current Qtr 09/30/18
See More
  • Average Estimate -0.59
  • Number of Estimates 6
  • High Estimate -0.49
  • Low Estimate -0.63
  • Prior Year -0.35
  • Growth Rate Est. (year over year) -68.57%

Price Performance

See More
Period Period Low Period High Performance
1-Month
10.30 +12.14%
on 09/17/18
15.93 -27.50%
on 09/17/18
-1.65 (-12.50%)
since 08/24/18
3-Month
8.76 +31.85%
on 07/19/18
20.19 -42.79%
on 06/26/18
-8.34 (-41.93%)
since 06/25/18
52-Week
8.76 +31.85%
on 07/19/18
23.96 -51.79%
on 05/29/18
-6.21 (-34.97%)
since 09/25/17

Most Recent Stories

More News
Mersana Therapeutics Presents New Preclinical Data on XMT-1536 at the International Association for the Study of Lung Cancer (IASLC) 19th World Conference on Lung Cancer

Novel Immunohistochemistry Assay Distinguishes Non-Small Cell Lung Cancer (NSCLC) Subtypes

MRSN : 11.55 (+1.49%)
Mersana Announces FDA Lifts Partial Clinical Hold for XMT-1522

Mersana Therapeutics, Inc. (NASDAQ:MRSN), a clinical-stage biopharmaceutical company focused on discovering and developing a pipeline of antibody drug conjugates (ADCs) based on its Dolaflexin and other...

MRSN : 11.55 (+1.49%)
Mersana Therapeutics to Present at Upcoming Investor Conferences

Mersana Therapeutics, Inc. (NASDAQ:MRSN), a clinical-stage biopharmaceutical company focused on discovering and developing a pipeline of antibody drug conjugates (ADCs) based on its Dolaflexin(R) and other...

MRSN : 11.55 (+1.49%)
Mersana Therapeutics, Inc. to Host Earnings Call

NEW YORK, NY / ACCESSWIRE / August 15, 2018 / Mersana Therapeutics, Inc. (NASDAQ: ) will be discussing their earnings results in their Q2 Earnings Call to be held on August 15, 2018 at 8:00 AM Eastern...

MRSN : 11.55 (+1.49%)
Mersana Therapeutics Announces Second Quarter 2018 Financial Results and Provides Business Updates

Response to the FDA Partial Clinical Hold Submitted This Week

MRSN : 11.55 (+1.49%)
Mersana Therapeutics to Host Conference Call Announcing Second Quarter 2018 Financial Results and Business Updates

Mersana Therapeutics, Inc. (NASDAQ:MRSN), a clinical-stage biopharmaceutical company focused on discovering and developing a pipeline of antibody drug conjugates (ADCs) based on its Dolaflexin(R) and other...

MRSN : 11.55 (+1.49%)
Mersana Therapeutics Announces First Quarter 2018 Financial Results and Provides Business Updates

Phase 1 Dose Escalation Trials Progressing for Lead Programs XMT-1522 and XMT-1536

MRSN : 11.55 (+1.49%)
Mersana Therapeutics to Host Conference Call Announcing First Quarter 2018 Financial Results and Business Updates

Mersana Therapeutics, Inc. (NASDAQ:MRSN), a clinical-stage biopharmaceutical company focused on discovering and developing a pipeline of antibody drug conjugates (ADCs) based on its Dolaflexin and other...

MRSN : 11.55 (+1.49%)
Mersana Therapeutics to Present at the Deutsche Bank 43rd Annual Health Care Conference

Mersana Therapeutics, Inc. (NASDAQ:MRSN), a clinical-stage biopharmaceutical company focused on discovering and developing a pipeline of antibody drug conjugates (ADCs) based on its Dolaflexin and other...

MRSN : 11.55 (+1.49%)
DB : 12.15 (-0.74%)
Wired News - Krystal Biotech's Lead Product Candidate, KB103, for Treatment of DEB Receives Orphan Medicinal Product Designation in Europe

Stock Monitor: Mersana Therapeutics Post Earnings Reporting

MRSN : 11.55 (+1.49%)

Barchart Technical Opinion

The Barchart Technical Opinion rating is a 72% Sell with a Average short term outlook on maintaining the current direction.

Longer term, the trend strength is Strong. Long term indicators fully support a continuation of the trend.

See More Share

Trade MRSN with:

Business Summary

Mersana Therapeutics, Inc. is a biotechnology company. It focused on discovering and developing a pipeline of antibody drug conjugates. The company's product candidates include XMT-1522 and XMT-1536 which are in clinical stage. Mersana Therapeutics, Inc. is based in CAMBRIDGE, United States.

See More

Key Turning Points

2nd Resistance Point 11.88
1st Resistance Point 11.71
Last Price 11.55
1st Support Level 11.39
2nd Support Level 11.24

See More

52-Week High 23.96
Fibonacci 61.8% 18.15
Fibonacci 50% 16.36
Fibonacci 38.2% 14.57
Last Price 11.55
52-Week Low 8.76

See More

Add Data Columns to this Table
Learn about our Custom Views
Want to use this as
your default charts setting?
Learn about our Custom Templates
Switch the Market flag
above for targeted data.
Open the menu and switch the
Market flag for targeted data.
Get Streaming Chart Updates
Switch your Site Preferences
to Interactive Chart
Need More Chart Options?
Right-click on the chart to open the Interactive Chart menu.

Free Barchart Webinar